Vero Cells-based In Vitro Screening Service

Unlocking Vital Insights with Vero Cells

Vero cells are initially collected from the kidneys of normal adult Cercopithecus aethiops and immortalized through a spontaneous and unknown process. After intensive research by scientists, the Vero cell has been rated as a suitable and safe biological resource. Vero cells are also a versatile in vitro model that can be effectively used to assess the effects of glycans on cell proliferation, metabolism, and toxicity. In addition, Vero cells can be used to research the interaction between glycans and viral infections, especially some glycan-related viruses (e.g., HIV, influenza virus, etc.).

As a professional engaged in a glycobiology research company, CD BioGlyco has developed several types of Glycobiology Disease Models, which cover a rich range of In Vivo and In Vitro Glycobiology Disease model types. Here, we offer our clients a professional Vero cells-based in vitro screening service.

• Vero cell line construction
  Knockdown not only gives Vero cells the ability to generate human glycosylation profiles and establish regulatory records but also offers multiple advantages. It is simple to perform and allows for the rapid generation of recombinant proteins through transient gene expression, which can be used for stable recombinant protein production. We use the knockdown cutting efficiency system to generate gene-edited Vero cell lines for targeted sequencing of specific genomic loci.
  According to the scientific needs of our clients, we perform the design of gene-stable knockout programs in combination with the target genes.
  • Small fragment knockout program: gRNA is located in introns at both ends of exons, knockout of exon coding can result in shifting codes.
  • Shifted code knockout scheme: gRNA is located in exons, and specific bases can be knocked out to cause shifted code mutations.
  • Large segment knockout protocol: the entire coding sequence of the gene is knocked out, resulting in a large segment knockout.
• Vero cell cytotoxicity assay
  3-(4,5-Dimethyl thiazol-2-yl)-5-diphenyl tetrazolium bromide (MTT) can be reduced by the mitochondrial enzyme succinate dehydrogenase to the blue color formazan and the amount of formazan produced is proportional to the number of active cells. Therefore, we utilize the MTT assay to screen for cytotoxicity in the Vero cell line and to determine semi-inhibitory concentration values.
  Different concentrations of the test drug are added to our microtitre plates containing Vero cells, which are then incubated in a specific gaseous environment. After some time, the same amount of MTT is added to each well. The absorbance is measured at a wavelength of 540 nm using an enzyme marker and the half inhibitory concentration value (CTC50) value is calculated.
• In vitro glycan uptake assessment in Vero cells
  Skeletal muscle is the main tissue involved in insulin-induced stimulation of glycan uptake. Insulin in skeletal muscle increases glycan uptake by increasing functional glycan transporter molecules on the plasma membrane. Vero cells are an excellent in vitro model of glycan uptake and are the most typical cell model for researching glycan uptake. Based on cytotoxicity assays, we evaluate the uptake of glycans by Vero cells.
  We perform the research in differentiated Vero cells.
  • Firstly, Vero cells are cultured in a petri dish and Vero cells are differentiated by adding bovine serum to the petri dish. In this, the degree of cell differentiation is determined by observing the multinucleation of the cells.
  • Next, a specific glycan solution is added to the differentiated cells and incubated at room temperature. After incubation, the uptake of the glycan is terminated by washing with a buffer solution.
  • Ultimately, we determine the level of glycans in the cell lysate using a glycan kit.

Publication Data

Advantages

• We develop the most appropriate in vitro glycobiology disease models based on Vero cells to meet our client's needs.
• We use biological tools to help our clients construct cell models and provide custom in vitro glycobiology disease screening services.
• We help clients around the world construct glycobiology disease models, and our models cover both in vivo and in vitro to ensure that we meet our clients' experimental requirements.

For many years, CD BioGlyco has gained a lot of experience and recognition in the development of glycobiology disease models. Please feel free to contact us if you have any needs in the field of glycobiology disease models, we will develop and provide satisfactory answers for you.